Heads up!
We’ve moved some things around. Take a quick tour to learn what has changed.
Take the tour
No thanks!
Thonzylamine
Identification
- Name
- Thonzylamine
- Accession Number
- DB11235
- Description
Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Thonzylamine (DB11235)
- Weight
- Average: 286.379
Monoisotopic: 286.179361344 - Chemical Formula
- C16H22N4O
- Synonyms
- neohetramine
- Thonzylamine
Pharmacology
- Indication
Thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms Label. It is typically a part of combination over the counter products.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Thonzylamine is a first-generation antihistamine. It antagonizes the action of histamine to relief allergic symptoms like nasal congestion, runny nose, itchy eyes, itchy nose and throat, and sneezing Label,1
- Mechanism of action
Thonzylamine competes with histamine for binding to the H1 histamine receptor 1. Binding of histamine to this receptor stimulates vasodilation and increased vascular permeability leading to nasal congestion and runny nose 3. Histamine also produces itchiness by stimulating nerve endings which can result in sneezing. By blocking these effects, thonzylamine can reduce or eliminate symptoms of allergic rhinitis.
Target Actions Organism AHistamine H1 receptor antagonistHumans UMuscarinic acetylcholine receptor M1 antagonistHumans UMuscarinic acetylcholine receptor M2 antagonistHumans UMuscarinic acetylcholine receptor M3 antagonistHumans UMuscarinic acetylcholine receptor M4 antagonistHumans UMuscarinic acetylcholine receptor M5 antagonistHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
Doses of up to 300 mg/day for up to 4 days have produces no observable toxic effects in humans 2. In a chronic toxicity study, rats were given up to 200 mg/kg/day orally for 91 days with no observable toxic effects 1.
- Affected organisms
- Not Available
- Pathways
Pathway Category Thonzylamine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Acetophenazine Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Aclidinium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Thonzylamine. Agomelatine Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Thonzylamine. Alimemazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Thonzylamine. Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Alosetron Alosetron may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Thonzylamine hydrochloride 6K9YKD48Y4 63-56-9 HRYJPHOTGFERGT-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Nasopen PE Thonzylamine hydrochloride (50 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL) Liquid Oral GM Pharmaceuticals, INC 2012-10-03 Not applicable US 
Poly Hist PD Thonzylamine hydrochloride (6.25 mg/1mL) + Chlophedianol hydrochloride (6.25 mg/1mL) Liquid Oral Poly Pharmaceuticals, Inc. 2013-07-01 Not applicable US Poly-Hist DM Thonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide monohydrate (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL) Liquid Oral Poly Pharmaceuticals, Inc. 2013-06-22 Not applicable US TexaClear Kids Sinus Relief Thonzylamine hydrochloride (50 mg/30mL) + Phenylephrine hydrochloride (5 mg/30mL) Liquid Oral GM Pharmaceuticals, INC 2015-06-15 2019-01-16 US Vanacof Ape Thonzylamine hydrochloride (50 mg/15mL) + Chlophedianol hydrochloride (25 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL) Liquid Oral Gm Pharmaceuticals 2012-10-03 2014-09-30 US
Categories
- ATC Codes
- D04AA01 — Thonzylamine
- D04AA — Antihistamines for topical use
- D04A — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D04 — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D — DERMATOLOGICALS
- R06AC — Substituted ethylene diamines
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- Drug Categories
- Agents producing tachycardia
- Antiallergic Agents, Excl. Corticosteroids
- Anticholinergic Agents
- Antihistamines for Systemic Use
- Antihistamines for Topical Use
- Antipruritics, Incl. Antihistamines, Anesthetics, Etc.
- Dermatologicals
- Histamine Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Muscarinic Antagonists
- Nasal Preparations
- Neurotransmitter Agents
- Substituted Ethylene Diamines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Anisoles
- Direct Parent
- Anisoles
- Alternative Parents
- Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Benzylamines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Alkyl aryl ether / Amine / Aminopyrimidine / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzylamine / Dialkylarylamine / Ether / Heteroaromatic compound show 13 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- R79646H5Z8
- CAS number
- 91-85-0
- InChI Key
- GULNIHOSWFYMRN-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3
- IUPAC Name
- N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine
- SMILES
- COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1
References
- General References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
- Chapter 39: Histamine, Bradykinin, and Their Antagonists. (2018). In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. [ISBN:978-1-25-958473-2]
- External Links
- Human Metabolome Database
- HMDB0240222
- PubChem Compound
- 5457
- PubChem Substance
- 347827947
- ChemSpider
- 5258
- 1360721
- ChEBI
- 104017
- ChEMBL
- CHEMBL1623738
- ZINC
- ZINC000000057513
- Wikipedia
- Thonzylamine
- FDA label
- Download (190 KB)
- MSDS
- Download (82.2 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 173-176 Scudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99. water solubility Highly Soluble Scudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99. - Predicted Properties
Property Value Source Water Solubility 0.733 mg/mL ALOGPS logP 2.4 ALOGPS logP 2.42 ChemAxon logS -2.6 ALOGPS pKa (Strongest Basic) 8.62 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 41.49 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 86.19 m3·mol-1 ChemAxon Polarizability 32.42 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-05fr-9720000000-8a7d4d036feab1e4ee54 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Guanyl-nucleotide exchange factor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM4
- Uniprot ID
- P08173
- Uniprot Name
- Muscarinic acetylcholine receptor M4
- Molecular Weight
- 53048.65 Da
References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM5
- Uniprot ID
- P08912
- Uniprot Name
- Muscarinic acetylcholine receptor M5
- Molecular Weight
- 60073.205 Da
References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [PubMed:18858080]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [PubMed:18888474]
Drug created on December 03, 2015 09:51 / Updated on June 12, 2020 10:53
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg","ThriveHealth-1.jpg":"/assets/ads/ThriveHealth-1-fe42678c71bf2ec7d508fde77efbe9f0aa868c5fa03bd39a7e1c97cefac0fa9d.jpg","ThriveHealth-2.jpg":"/assets/ads/ThriveHealth-2-32bb14bb00de8a1b2efc2a51ce37f490c01e76dac7b9c09b6b831c50640b6567.jpg","ThriveHealth-3.jpg":"/assets/ads/ThriveHealth-3-e184eae1745f8aa22525b294b761ee89f5a854a434d50e5d6d37c0b77f2cf523.jpg","ThriveHealth-4.jpg":"/assets/ads/ThriveHealth-4-218f710e6d20831711d0920e585b986217c38f38d9849b8dd32bb56f68d2eea9.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates